167 related articles for article (PubMed ID: 20666580)
1. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Zilberberg MD; Mody SH; Chen J; Shorr AF
Surg Infect (Larchmt); 2010 Oct; 11(5):409-17. PubMed ID: 20666580
[TBL] [Abstract][Full Text] [Related]
2. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
McGarry LJ; Merchant S; Nathwani D; Pawar V; DeLong K; Thompson D; Akhras K; Ingham M; Weinstein MC
J Med Econ; 2010 Mar; 13(1):142-7. PubMed ID: 20136579
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Kollef MH; Chastre J; Clavel M; Restrepo MI; Michiels B; Kaniga K; Cirillo I; Kimko H; Redman R
Crit Care; 2012 Nov; 16(6):R218. PubMed ID: 23148736
[TBL] [Abstract][Full Text] [Related]
4. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Merchant S; Gast C; Nathwani D; Lee M; Quintana A; Ketter N; Friedland I; Ingham M
Clin Ther; 2008 Apr; 30(4):717-33. PubMed ID: 18498921
[TBL] [Abstract][Full Text] [Related]
5. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.
Nicasio AM; Eagye KJ; Kuti EL; Nicolau DP; Kuti JL
Pharmacotherapy; 2010 May; 30(5):453-62. PubMed ID: 20411997
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
7. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
[TBL] [Abstract][Full Text] [Related]
8. Doripenem: excess mortality.
Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016255
[No Abstract] [Full Text] [Related]
9. Clinical and economic consequences of ventilator-associated pneumonia.
Amin A
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S36-43. PubMed ID: 19619020
[TBL] [Abstract][Full Text] [Related]
10. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Crandon JL; Luyt CE; Aubry A; Chastre J; Nicolau DP
J Antimicrob Chemother; 2016 Sep; 71(9):2534-7. PubMed ID: 27272723
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure.
Planquette B; Timsit JF; Misset BY; Schwebel C; Azoulay E; Adrie C; Vesin A; Jamali S; Zahar JR; Allaouchiche B; Souweine B; Darmon M; Dumenil AS; Goldgran-Toledano D; Mourvillier BH; Bédos JP;
Am J Respir Crit Care Med; 2013 Jul; 188(1):69-76. PubMed ID: 23641973
[TBL] [Abstract][Full Text] [Related]
13. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).
Mustafa M; Chan WM; Lee C; Harijanto E; Loo CM; Van Kinh N; Anh ND; Garcia J
Int J Antimicrob Agents; 2014 Apr; 43(4):353-60. PubMed ID: 24636429
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Nicasio AM; Eagye KJ; Nicolau DP; Shore E; Palter M; Pepe J; Kuti JL
J Crit Care; 2010 Mar; 25(1):69-77. PubMed ID: 19427167
[TBL] [Abstract][Full Text] [Related]
15. Utility of ampicillin-sulbactam for empiric treatment of ventilator-associated pneumonia in a trauma population.
McMillian WD; Bednarik JL; Aloi JJ; Ahern JW; Crookes BA
J Trauma; 2010 Oct; 69(4):861-5. PubMed ID: 20938272
[TBL] [Abstract][Full Text] [Related]
16. Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia.
Hibbard ML; Kopelman TR; O'Neill PJ; Maly TJ; Matthews MR; Cox JC; Vail SJ; Quan AN; Drachman DA
Surg Infect (Larchmt); 2010 Oct; 11(5):427-32. PubMed ID: 20818984
[TBL] [Abstract][Full Text] [Related]
17. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
[TBL] [Abstract][Full Text] [Related]
18. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.
Eagye KJ; Nicolau DP; Kuti JL
Semin Respir Crit Care Med; 2009 Feb; 30(1):116-23. PubMed ID: 19199193
[TBL] [Abstract][Full Text] [Related]
19. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
20. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
